Creso Pharma Limited
Melodiol Global Health Limited engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. It is involved in the development and commercialisation of nutraceutical products; and medical supplies business. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Hea… Read more
Creso Pharma Limited (COPHF) - Total Liabilities
Latest total liabilities as of December 2023: $23.10 Million USD
Based on the latest financial reports, Creso Pharma Limited (COPHF) has total liabilities worth $23.10 Million USD as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Creso Pharma Limited - Total Liabilities Trend (2015–2023)
This chart illustrates how Creso Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Creso Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Creso Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TCI Finance Limited
NSE:TCIFINANCE
|
India | ₹828.64 Million |
|
Emico Holdings Bhd
KLSE:9091
|
Malaysia | RM44.22 Million |
|
Spartoo SAS
PA:ALSPT
|
France | €50.45 Million |
|
WI Co. Ltd.
KQ:073570
|
Korea | ₩2.15 Billion |
|
Canada Rare Earth Corp
PINK:RAREF
|
USA | $3.26 Million |
|
General de Galerias Comerciales SOCIMI S.A.
MC:GGC
|
Spain | €191.02 Million |
|
Izolacja Jarocin SA
WAR:IZO
|
Poland | zł-18.39 Million |
Liability Composition Analysis (2015–2023)
This chart breaks down Creso Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Creso Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Creso Pharma Limited (2015–2023)
The table below shows the annual total liabilities of Creso Pharma Limited from 2015 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $23.10 Million | +47.26% |
| 2022-12-31 | $15.69 Million | +908.55% |
| 2021-12-31 | $1.56 Million | -71.56% |
| 2020-12-31 | $5.47 Million | +1.46% |
| 2019-12-31 | $5.39 Million | -6.72% |
| 2018-12-31 | $5.78 Million | +918.55% |
| 2017-12-31 | $567.27K | +7.43% |
| 2016-12-31 | $528.02K | +292.15% |
| 2016-06-30 | $134.65K | +1063.57% |
| 2015-12-31 | $11.57K | -- |